TORONTO, Sept. 21 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the introduction and adoption of new growth factors, combined with greater variety and improved features of newer products, will drive the US bone graft substitute market to nearly $2.3 billion through 2015.
Medtronic Spinal & Biologics' new bone morphogenetic protein, AMPLIFY, is set to be released in the US market in 2011. Unlike INFUSE, however, AMPLIFY is combined with a collagen and ceramic matrix designed for implantation in single-level posterolateral lumbar fusions—an indication that current bone morphogenetic proteins do not have approval for. BioMimetic Therapeutics' Augment Bone Graft is also set to enter the US market in 2011. The device's platelet-derived growth factor is touted by BioMimetic Therapeutics for having five times the rate of chemotaxis (the ability to recruit stem cells) and the ability to stimulate the replication of osteoblasts, not normally typical of bone morphogenetic proteins.
Orthopedic stem cell products, such as NuVasive's Osteocel Plus, Orthofix's Trinity Evolution, or AlloSource's AlloStem, contain stem cells that can differentiate into a variety of tissue cells to promote bone healing. Such products offer superior effectiveness compared with many alternative substitutes. Second-generation synthetic products, such as Orthovita's Vitoss BA and Baxter's Actifuse have integrated bioactive components that increase osteoinductivity and thus accelerate bone growth and healing. The improved features of these products will promote surgeon adoption of these materials over autografts, while their higher prices compared to older generation products will contribute to revenue growth over the next five years.
"Surgeons certainly have a plethora of choice when it comes to bone graft substitutes," says Deanna Vankessel, Senior Analyst at MRG. "The increased marketing that will follow the pending approval of AMPLIFY and Augment will contribute to even greater awareness of all of the viable alternatives to the conventional, yet gold-standard, autograft harvesting technique."
MRG's US Markets for Orthopedic Biomaterials 2010 report provides critical insight into emerging trends that will fuel product adoption and market growth for bone graft substitutes, hyaluronic acid viscosupplementation, machined bone interbody devices, cell concentration systems, and knee cartilage repair treatments in the US through 2015. Additionally, the report provides a complete breakdown of procedure volumes, unit sales, average selling prices, and revenues by device type. This report includes five-year forecasts, up-to-date market shares, and in-depth qualitative insights.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. firstname.lastname@example.orgChris Comfort
Decision Resources Inc.
|SOURCE Millennium Research Group|
Copyright©2010 PR Newswire.
All rights reserved